Overcoming limitations in the systems vaccinology approach: A pathway for accelerated HIV vaccine development

Current Opinion in HIV and AIDS

Volumn 7, Issue 1, 2012, Pages 58-63

  Zak, Daniel E ^a   Aderem, Alan ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

HIV vaccine; Innate immunity; Systems biology; Systems immunology; Systems vaccinology

Indexed keywords

BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; BLOOD SAMPLING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY;

AIDS VACCINES; ANIMALS; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; IMMUNOLOGIC TECHNIQUES; SYSTEMS BIOLOGY;

EID: 84857052591     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834ddd31     Document Type: Review

References (46)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
2. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
3. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366-371. This study demonstrated that the Step study vaccine, despite a lack of efficacy, exerted selective pressure on the infecting virus.
4. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
5. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473: 523-527. This study demonstrates how a persistent vaccine vector can lead to remarkable viral control in the SIV model.
6. Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009; 4:431-440.
7. Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010; 31:120-130.
8. Perrin H, Canderan G, Sekaly RP, Trautmann L. New approaches to design HIV-1 T-cell vaccines. Curr Opin HIV AIDS 2010; 5:368-376.
9. Thomas PG, Doherty PC. Rules to 'prime' by. Nat Immunol 2009; 10:14-16.
10. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7:19-23. (Pubitemid 41823864)
11. Sander LE, Davis MJ, Boekschoten MV, et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011; 474:385-389. This study demonstrates how the immunogenicity of live pathogens can be recapitulated by including appropriate microbial components as adjuvants in a vaccine formulation.
12. Amit I, Garber M, Chevrier N, et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 2009; 326:257-263.
13. Zak DE, Schmitz F,Gold ES, et al. Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. Proc Natl Acad Sci U S A 2011; 108:11536-11541.
14. Litvak V, Ramsey SA, Rust AG, et al. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol 2009; 10:437-443.
15. Ramsey SA, Klemm SL, Zak DE, et al. Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. PLoS Comput Biol 2008; 4:e1000021.
16. Gilchrist M, Thorsson V, Li B, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006; 441:173-178.
17. Suzuki H, Forrest AR, van Nimwegen E, et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet 2009; 41:553-562.
18. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.
19. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-3131.
20. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786-795. This study is the first to complete the iterative systems vaccinology cycle by using a mouse knockout model to validate immunogenicity signatures identified from vaccinated humans.
21. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010; 33:516-529.
22. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463-469.
23. Zak DE, Aderem A. Systems biology of innate immunity. Immunol Rev 2009; 227:264-282.
24. Shapira SD, Hacohen N. Systems biology approaches to dissect mammalian innate immunity. Curr Opin Immunol 2011; 23:71-77.
25. Gardy JL, Lynn DJ, Brinkman FS, Hancock RE. Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol 2009; 30:249-262.
26. Longabaugh WJ, Davidson EH, Bolouri H. Visualization, documentation, analysis, and communication of large-scale gene regulatory networks. Biochim Biophys Acta 2009; 1789:363-374.
27. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63.
28. Bosinger SE, Li Q, Gordon SN, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009; 119:3556-3572.
29. Palermo RE, Patterson LJ, Aicher LD, et al. Genomic analysis reveals pre and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol 2011; 85:1099-1116.
30. Baum LL. Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010; 7:11-18.
31. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258. (Pubitemid 351432801)
32. Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011; 6:169-173.
33. + T-cell responses.
34. Fonseca SG, Procopio FA, Goulet JP, et al. Unique features of memory T cells in HIV elite controllers: a systems biology perspective. Curr Opin HIV AIDS 2011; 6:188-196.
35. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
36. Walker BD. Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 2007; 15:134-136.
37. Rolland M, Gilbert P. Evaluating immune correlates in HIV-1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses 2011.
38. Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS Rev 2011; 13:135-148.
39. Baroncelli S, Negri DR, Michelini Z, Cara A. Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines 2008; 7:1419-1434.
40. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-424. (Pubitemid 43290850)
41. Lindsay RW, Darrah PA, Quinn KM, et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 2010; 185:1513-1521.
42. Delaloye J, Roger T, Steiner-Tardivel QG, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5:e1000480.
43. Brooks JPL, Lee EK. Analysis of the consistency of a mixed integer programming-based multicategory constrained discriminant model. Ann Oper Res 2008: 174:147-168.
44. Zou HH, Hastie T. regularization and variable selection via the Elastic Net. J R Stat Soc B 2005; 67:301-320. (Pubitemid 40465877)
45. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-112.
46. Tan X, Sande JL, Pufnock JS, et al. Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge. J Virol 2011; 85:8316-8327. This study demonstrates how co-administration of a small molecule selective pathway agonist with a vaccine can dramatically alter the vaccine-induced adaptive immune response.